Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 1
1976 17
1977 1
1978 4
1979 2
1980 4
1981 6
1982 2
1983 2
1984 3
1985 8
1986 12
1987 7
1988 10
1989 10
1990 18
1991 11
1992 14
1993 15
1994 20
1995 28
1996 21
1997 34
1998 20
1999 45
2000 37
2001 27
2002 29
2003 33
2004 36
2005 40
2006 49
2007 55
2008 56
2009 54
2010 55
2011 55
2012 60
2013 63
2014 71
2015 65
2016 55
2017 64
2018 56
2019 53
2020 55
2021 57
2022 46
2023 46
2024 40
2025 44
2026 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,455 results

Results by year

Filters applied: . Clear all
Page 1
Bupropion and Naltrexone in Methamphetamine Use Disorder.
Trivedi MH, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T, Ghitza UE, Wahle A, Kim M, Shores-Wilson K, Sparenborg S, Coffin P, Schmitz J, Wiest K, Bart G, Sonne SC, Wakhlu S, Rush AJ, Nunes EV, Shoptaw S. Trivedi MH, et al. N Engl J Med. 2021 Jan 14;384(2):140-153. doi: 10.1056/NEJMoa2020214. N Engl J Med. 2021. PMID: 33497547 Free PMC article. Clinical Trial.
BACKGROUND: The use of naltrexone plus bupropion to treat methamphetamine use disorder has not been well studied. ...In the first stage, 18 of 109 participants (16.5%) in the naltrexone-bupropion group and 10 of 294 (3.4%) in the placebo group had a response. In the …
BACKGROUND: The use of naltrexone plus bupropion to treat methamphetamine use disorder has not been well studied. ...In the first sta …
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial.
Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R. Grilo CM, et al. Am J Psychiatry. 2022 Dec 1;179(12):927-937. doi: 10.1176/appi.ajp.20220267. Epub 2022 Oct 26. Am J Psychiatry. 2022. PMID: 36285406 Free PMC article. Clinical Trial.
RESULTS: Intention-to-treat binge-eating remission rates were 17.7% in the placebo group, 31.3% in the naltrexone-bupropion group, 37.1% in the BWL+placebo group, and 57.1% in the BWL+naltrexone-bupropion group. ...The rates of participants attaining 5% weight loss …
RESULTS: Intention-to-treat binge-eating remission rates were 17.7% in the placebo group, 31.3% in the naltrexone-bupropion group, 37 …
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group. Greenway FL, et al. Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29. Lancet. 2010. PMID: 20673995 Clinical Trial.
Mean change in bodyweight was -1.3% (SE 0.3) in the placebo group, -6.1% (0.3) in the naltrexone 32 mg plus bupropion group (p<0.0001 vs placebo) and -5.0% (0.3) in the naltrexone 16 mg plus bupropion group (p<0.0001 vs placebo). 84 (16%) participants assigned …
Mean change in bodyweight was -1.3% (SE 0.3) in the placebo group, -6.1% (0.3) in the naltrexone 32 mg plus bupropion group (p<0.0 …
Oral vs Extended-Release Injectable Naltrexone for Hospitalized Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
Magane KM, Dukes KA, Fielman S, Palfai TP, Regan D, Cheng DM, Lee H, Kraemer KL, Bullard MJ, Chen CA, Samet JH. Magane KM, et al. JAMA Intern Med. 2025 Jun 1;185(6):635-645. doi: 10.1001/jamainternmed.2025.0522. JAMA Intern Med. 2025. PMID: 40257810 Free PMC article. Clinical Trial.
The comparative effectiveness between initiation of oral naltrexone and extended-release injectable naltrexone in the hospital is not known. OBJECTIVE: To compare the effectiveness of initiating oral naltrexone vs extended-release injectable naltrexone …
The comparative effectiveness between initiation of oral naltrexone and extended-release injectable naltrexone in the hospital …
Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.
Morley KC, Kranzler HR, Luquin N, Jamshidi N, Adams C, Montebello M, Tremonti C, Dali G, Logge W, Baillie A, Teesson M, Trent R, Haber PS. Morley KC, et al. Am J Psychiatry. 2024 May 1;181(5):403-411. doi: 10.1176/appi.ajp.20230666. Am J Psychiatry. 2024. PMID: 38706338 Clinical Trial.
There were significant time-by-treatment effects, with greater reductions observed with topiramate than naltrexone for BMI, craving, and gamma-glutamyltransferase level. Withdrawal due to side effects occurred in 8% and 5% of the topiramate and naltrexone groups, re …
There were significant time-by-treatment effects, with greater reductions observed with topiramate than naltrexone for BMI, craving, …
Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial.
Due Bruun K, Christensen R, Amris K, Vaegter HB, Blichfeldt-Eckhardt MR, Bye-Møller L, Holsgaard-Larsen A, Toft P. Due Bruun K, et al. Lancet Rheumatol. 2024 Jan;6(1):e31-e39. doi: 10.1016/S2665-9913(23)00278-3. Epub 2023 Dec 5. Lancet Rheumatol. 2024. PMID: 38258677 Clinical Trial.
BACKGROUND: Low-dose naltrexone is used to treat fibromyalgia despite minimal evidence for its efficacy. This trial aimed to investigate whether 12-week treatment with 6 mg low-dose naltrexone was superior to placebo for reducing pain in women with fibromyalgia. ... …
BACKGROUND: Low-dose naltrexone is used to treat fibromyalgia despite minimal evidence for its efficacy. This trial aimed to investig …
Naltrexone and Alzheimer's disease.
Serby M, Resnick R, Jordan B, Adler J, Corwin J, Rotrosen JP. Serby M, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10(3-5):587-90. doi: 10.1016/0278-5846(86)90028-x. Prog Neuropsychopharmacol Biol Psychiatry. 1986. PMID: 3541052 Clinical Trial.
Any patient who showed cognitive/behavioral improvement on a given dose of naltrexone was then treated with this dosage in a double-blind crossover comparison to placebo. ...Only one of these patients improved during active naltrexone administration. We conclude tha …
Any patient who showed cognitive/behavioral improvement on a given dose of naltrexone was then treated with this dosage in a double-b …
An open clinical trial of naltrexone for amphetamine dependence: compliance and tolerability.
Jayaram-Lindström N, Wennberg P, Beck O, Franck J. Jayaram-Lindström N, et al. Nord J Psychiatry. 2005;59(3):167-71. doi: 10.1080/08039480510023052. Nord J Psychiatry. 2005. PMID: 16195116 Clinical Trial.
The aim of the study was to assess the feasibility of naltrexone as a potential pharmacotherapy for amphetamine dependence. The study design was an open-label clinical trial with 20 amphetamine-dependent patients receiving 12 weeks of treatment comprised of naltrexone …
The aim of the study was to assess the feasibility of naltrexone as a potential pharmacotherapy for amphetamine dependence. The study …
Early Change in Depressive Symptom Severity With Naltrexone-Bupropion Combination and Its Association With Reduction in Methamphetamine Use in ADAPT-2 Trial.
Jha MK, Ghitza UE, Shoptaw S, Minhajuddin A, Kuruvila S, Wakhlu S, Nunes EV, Schmitz J, Coffin PO, Bart G, Carmody T, Trivedi MH. Jha MK, et al. J Clin Psychiatry. 2025 Jul 30;86(3):25m15825. doi: 10.4088/JCP.25m15825. J Clin Psychiatry. 2025. PMID: 40767786 Free PMC article. Clinical Trial.
Objective: This study evaluated whether depressive symptom severity improved early with extended-release naltrexone and bupropion combination (naltrexone bupropion) compared to a placebo in individuals with moderate/severe methamphetamine use disorder and predicted …
Objective: This study evaluated whether depressive symptom severity improved early with extended-release naltrexone and bupropion com …
Naltrexone for alcohol-dependent patients.
Ahmadi J, Babaeebeigi M, Maany I, Porter J, Mohagheghzadeh M, Ahmadi N, Dehbozorgi G. Ahmadi J, et al. Ir J Med Sci. 2004 Jan-Mar;173(1):34-7. doi: 10.1007/BF02914522. Ir J Med Sci. 2004. PMID: 15732235 Clinical Trial.
BACKGROUND: Clinical trials have shown that naltrexone 50 mg/day reduces alcohol consumption and relapse rates in alcohol dependents. ...CONCLUSION: The results support the efficacy and safety of naltrexone for outpatient treatment of alcohol-dependent individuals i …
BACKGROUND: Clinical trials have shown that naltrexone 50 mg/day reduces alcohol consumption and relapse rates in alcohol dependents. …
1,455 results